Compare stocks

Embla Medical hf., headquartered in Reykjavik, Iceland, specializes in non-invasive orthopedic products, focusing on prosthetics, neuro orthotics, bracing, and supports. The company operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. Its product portfolio includes mechanical and bionic prosthetic devices, bracing solutions for various body parts, and patient care services for individuals with limb loss or musculoskeletal conditions. Originally founded as Össur hf. in 1971, the company rebranded to Embla Medical hf. in April 2024 to reflect its expanded scope and unified purpose. Embla Medical serves a global market, with operations across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's strategic positioning is strengthened by its diverse brand portfolio, including Össur, Fior & Gentz, College Park, and ForMotion, enabling it to offer comprehensive mobility solutions worldwide.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.